AstraZeneca Acquisitions and Exits, 24 Deals Between 2005 and 2018
life science Company

AstraZeneca has acquired 14 companies, including 5 in the last 5 years. A total of 4 acquisitions came from private equity firms. It has also divested 11 assets.

AstraZeneca’s largest acquisition to date was in 2007, when it acquired MedImmune for $15.6B. It’s largest disclosed sale occurred in 2016, when it sold AstraZeneca - Small Molecule Anti-Infective Business to Pfizer for $550M. AstraZeneca has acquired in 5 different US states, and 6 countries. The Company’s most targeted sectors include life science (77%) and information technology (8%).

Join Mergr and gain access to AstraZeneca’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.

AstraZeneca Plc

2 Kingdom Street,
London, W2 6BD
United Kingdom,
44 20 7604 8000
www.astrazeneca.com

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biologics company .AstraZeneca is an innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca was formed in 1992 and is based in London.

M&A Summary

Buy vs Sell

Year ≤ '14 '15 '16 '17 '18 '19 T
Buy (0.6/yr) # 10 3 - - - - 13
vol $21.5B $7.3B $28.8B
Sell (1.0/yr) # 6 1 2 - 2 - 11
vol $550M $725M $350M $1.6B
  24

Top M&A Advisors

Financial Deals
Sign-up to View
1
Legal Deals
Join to Access.

Deal Values

Buy # TOTAL
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
TOTAL Sign-up to View
Largest MedImmune LLC
$15.6B (2007-06-01)
Sell # Total
> $1B Sign-up to View
$100M to $1B Sign-up to View
< $100M Sign-up to View
Total Sign-up to View
Largest AstraZeneca - Small Molecule Anti-Infective Business
$550M (2016-08-24)

Life Science M&A - Last 3 Years

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 378 life science companies that have made at least 1 acquisition, 17 have acquired at least 5 companies, and 2 have acquired more than 10 companies.

The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 23 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Avista Capital Partners with 6 platform acquisitions.


What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 3.7K Private Equity Firms
  • 131K M&A Transactions
  • 140K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.0K M&A Advisors
    (Investment Banks and Law Firms)
  • 37K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.